Abstract Search

ea0099rc5.4 | Rapid Communications 5: Pituitary and Neuroendocrinology | Part I | ECE2024

A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-3813, a novel, small peptide growth hormone receptor antagonist, in healthy subjects

Allas Soraya , Ravel Guillaume , Farrell Colm , Fillon Sophie , Ould Rouis Taha , Culler Michael , Ovize Michel , Sumeray Mark , van der Lelij Aart Jan

Background: Acromegaly is a rare disease typically caused by a benign growth hormone (GH)-secreting pituitary adenoma that stimulates over-production of insulin-like growth factor-1 (IGF1) from the liver. Treatment with somatostatin analog (SSA) monotherapy does not provide optimal control of circulating IGF-1 levels in the majority of patients. AZP-3813, a 16-amino acid, bicyclic GH receptor antagonist (GHRA) binds to the GH receptor and prevents endogenous GH from stimulatin...

0 shares

Endocrine Abstracts

A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-3813, a novel, small peptide growth hormone receptor antagonist, in healthy subjects

BiosciAbstracts